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Abstract
The case-crossover design (Maclure, 1991) is widely used in epidemiology and other fields
to study causal effects of transient treatments on acute outcomes. However, its validity
and causal interpretation have only been justified under informal conditions. Here, we
place the design in a formal counterfactual framework for the first time. Doing so helps to
clarify its assumptions and interpretation. In particular, when the treatment effect is non-
null, we identify a previously unnoticed bias arising from common causes of the outcome
at different person-times. We analytically characterize the direction and size of this bias
and demonstrate its potential importance with a simulation. We also use our derivation
of the limit of the case-crossover estimator to analyze its sensitivity to treatment effect
heterogeneity, a violation of one of the informal criteria for validity. The upshot of this work
for practitioners is that, while the case-crossover design can be useful for testing the causal
null hypothesis in the presence of baseline confounders, extra caution is warranted when
using the case-crossover design for point estimation of causal effects.
1 Introduction
The case-crossover design (Maclure, 1991) is used in epidemiology and other fields to study causal
effects of transient treatments on acute outcomes. A major advantage of the case-crossover design
is that it only requires information from individuals who experience the outcome of interest (the
cases). In a seminal application of this design (Mittleman et al., 1993), researchers obtained
data on the physical activity (a transient treatment) of individuals who experienced a myocardial
infarction (MI, an acute outcome). They then defined any person-times less than one hour after
vigorous activity as ‘treated’, and all other person-times as ‘untreated’. Finally, they considered
each person-time as an individual observation and computed a Mantel-Haenszel estimate of the
corresponding hazard ratio (Tarone, 1981; Nurminen, 1981; Kleinbaum et al., 1982; Greenland
and Robins, 1985). This hazard ratio estimate was interpreted as the causal effect of vigorous
physical activity on MI. Some variants of the case-crossover design allow flexible control time
selection strategies where control times can follow outcome occurrence (Levy et al., 2001), but
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in this paper we restrict attention to studies of time to event outcomes in which follow-up is
terminated at the time of the first outcome occurrence as in the above MI example.
Past authors have extensively considered several threats to validity of the case-crossover de-
sign (Maclure, 1991; Vines and Farrington, 2001; Levy et al., 2001; Janes et al., 2005; Mittleman
and Mostofsky, 2014), and conditions for causal interpretation of the estimator have been infor-
mally stated in the literature. The usual criteria cited are that:
(a) the outcome has acute onset;
(b) the treatment is transient;
(c) there are no unobserved post-baseline common causes of treatment and outcome;
(d) there are no time trends in treatment; and
(e) the treatment effect is constant across subjects.
Condition (e) is a consequence of using the Mantel-Haenszel odds ratio estimator. The
Mantel-Haenszel estimator was originally applied to estimate the treatment-outcome odds ra-
tio when subjects were classified in strata defined by the values of the confounders V , and the
observed subjects from each stratum could be conceived of as independent draws from the (hypo-
thetically) infinite stratum population. In fact, under the assumptions that the stratum-specific
odds ratios are all equal and the observations are independent within each stratum, the Mantel-
Haenszel estimator was proven consistent for the constant odds ratio as the number of strata
approach infinity even if only a few independent subjects are observed in each stratum (Breslow,
1981). Since the values of the confounders V are held constant within each stratum, the constant
odds ratio can be endowed with a causal interpretation if V includes all confounders. The same
goes for the rate ratio (Robins and Greenland, 1985).
Maclure’s idea was to regard person-times (rather than subjects) as the units of analysis
and subjects (rather than confounders) as the strata, then apply the Mantel-Haenszel odds ratio
estimator to estimate the assumed constant subject-specific hazard ratio. Because all baseline
covariates (e.g. sex, genes, etc.) are held constant within subjects, these subject-specific effect
estimates cannot be confounded by observed or unobserved baseline covariates. Thus, the case-
crossover design would seem to eliminate baseline confounding as a source of bias assuming
a constant hazard ratio across subjects and independent observations across time within each
subject. Of course, these two assumptions are unlikely to be met in most research settings: the
effect of treatment is rarely the same in all subjects, and variables at different person-times are
not expected to be independent within subjects. (Informal assumptions (a)-(d) can be viewed
as a more plausible alternative to independent person times.) But studying how violations of
these strong assumptions affect case-crossover estimates requires a formal description of the
case-crossover design.
Here we place the case-crossover design in a formal counterfactual causal inference framework
(Rubin, 1978; Robins, 1986). Doing so helps to clarify its assumptions and interpretation. The
organization of the paper is as follows. In Section 2, we introduce notation, describe the cohort
that gives rise to the data employed in a case-crossover analysis, and summarize two case-
crossover studies from the literature that will serve as running examples. In Section 3, we define
a natural estimand motivated by a hypothetical randomized trial that practitioners of the case-
crossover design might wish to emulate. In Section 4, we state formal assumptions (mostly
analogous to informal assumptions (a)-(e)) that allow us to causally interpret the limit of the
case-crossover estimator, which we find does not in general correspond to the trial estimand
from Section 3. We identify and characterize previously unnoticed bias present when there exist
common causes of the outcome at different person-times (as would seem likely in most instances)
and the treatment effect is non-null. In Section 5, we discuss this bias and illustrate it with a
simulation. We also use our results from Section 4 to analyze sensitivity to effect heterogeneity,
i.e. violations of informal assumption (e), through a simple example. In Section 6, we conclude.
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Our general message to practitioners is that, while the case-crossover can be a clever way to test
the null hypothesis of no causal effect in the presence of unobserved baseline confounding, its
point estimates of non-null effects can be sensitive to violations of unrealistic assumptions.
2 Data Generating Process
2.1 Notation
While case-crossover studies only use data from subjects who experience the outcome, we will
nonetheless describe a full cohort from which these subjects are drawn in order to facilitate the
definition of certain concepts and quantities of interest. Consider a cohort of individuals followed
from baseline (i.e. study entry)–defined by calendar time, age, or time of some pre-defined index
event–until they develop the outcome or the administrative end of follow-up, whichever occurs
first. For simplicity, we assume no individual is lost to follow-up. Subjects are indexed by
i, i ∈ {1, ..., N}. Subject i is followed for at most T person-times (e.g. hours) indexed by
j ∈ {0, . . . , T}. For simplicity we take T to be the same for all subjects. Let Aij be a binary
variable taking values 0 and 1 indicating whether subject i was treated at time j. Let Yij be
a binary variable taking values 0 and 1 indicating whether the outcome of interest occurred in
subject i before time j + 1. We assume that Yij is a ‘time to event’ outcome in the sense that
if Yij = 1 then Yij′ = 1 for all j′ > j. The above implies the temporal ordering Aij , Yij , Ai(j+1).
Thus the outcome has an acute onset as required by informal condition (a). If an outcome is
lasting or recurrent, we can consider the time of its first occurrence. We define Aij = 0 if the
event has occurred by time j, i.e. if Yi(j−1) = 1.
For a time-varying variable X, we denote by X¯ij the history (Xi0, . . . , Xij) of X in subject
i up (i.e. prior) to time j + 1. Let V denote a possibly multidimensional and unobserved
baseline confounding variable that we assume has some population density p(v). (For notational
convenience we shall write conditional probabilities P{·|·, V = v} given V = v as pv{·|·}. To avoid
measure theoretic subtleties we shall henceforth assume that when V has continuous components,
conditions sufficient to pick out a particular version of P{·|·, V = v} have been imposed as in
Gill and Robins (2001).) Let U¯T denote common causes of outcomes at different person-times
not included in V . For example, in the MI and exercise study, Uj could denote formation of a
blood clot by hour j after baseline. We assume that the N subjects are iid realizations of the
random vector (V, A¯T , Y¯T , U¯T ) and that Uj precedes Aj and Yj in the temporal ordering at each
j. Recall that in a case-crossover study the observed data on subject i are
(
A¯iT , Y¯iT
)
as data on
V and U¯T are not available.
We assume that the causal directed acyclic graph (DAG) in Figure 1 describes the data
generating process within levels of baseline confounders V . This DAG encodes aspects of informal
assumptions (b) and (c). One salient feature of the DAG is that there are no directed paths from
a current treatment to an outcome at a later time that do not first pass through the outcome at
the time of the current treatment or a later treatment. This can be considered a representation
of informal assumption (b) that treatment is transient. The DAG also excludes any common
causes of treatments and outcomes other than V not through past outcomes. (Since occurrence
of the outcome at time j determines the values of all variables at all later time points, outcome
variable nodes in the DAG trivially must have arrows to all temporally subsequent variables.)
This represents informal assumption (c) which bars non-baseline confounding. This DAG also
has fully forward connected treatments with arbitrary common causes of treatment at different
times U¯AT , indicating that we put no causal restrictions on the treatment assignment process.
(We will, however, impose distributional assumptions.) We provide a fuller discussion of causal
assumptions in Section 4, but we find it helpful to keep this DAG in mind.
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Figure 1: Causal DAG within levels of V . A V node with arrows pointing into every other node
was omitted for visual clarity.
2.2 Two Examples of the Case Crossover Design
The case-crossover estimator requires data from subjects who experience the outcome on treat-
ment status at the time of outcome occurrence and at designated ‘control’ times preceding the
outcome. Specifically, the estimator is computed as the ratio:∑
subjects
∑
control times 1{outcome time treated and control time untreated}∑
subjects
∑
control times 1{outcome time untreated and control time treated}
(1)
where we use 1{ } to denote an indicator function. Control times can be chosen in various ways.
Intuitively, the more subjects tend to be treated at the time of the outcome compared to at
earlier control times, the stronger the effect of treatment.
To fix ideas, we consider two examples of case-crossover studies from the literature. In a
simplified version of Mittleman et al.’s (1993) seminal study on the impact of exercise on MI
mentioned in the introduction, suppose we collect data from a random sample of patients suffering
MI on a particular Sunday. We record whether each sampled MI patient had exercised in the
hour immediately preceding their MI and also whether they had exercised in the same hour the
day before (i.e. Saturday, 24 hours before their MI). We compute the Mantel-Haenszel case-
crossover estimator ratio: in the numerator is the number of subjects who exercised immediately
prior to their MI but not 24 hours before, and in the denominator is the number of subjects
who did not exercise immediately prior to their MI but did 24 hours before. Mittleman et al.
estimated a ratio of 5.9 (95% CI 4.6,7.7). They also found that the ratio was much higher among
subjects who rarely exercised (107, 95% CI 67,171) than among patients who exercised regularly
(2.4, 95% CI 1.5,3.7).
In another example, Ki et al. (2003) were interested in the effect of measles-mumps-rubella
(MMR) vaccination on aseptic meningitis (AM) in Korean children. AM is a known potential
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side effect of the MMR vaccine, but its rarity varies across populations and vaccine strains.
They obtained the timing of any past MMR vaccination for children who had confirmed AM
diagnoses, defining subjects to be treated for 42 days after receiving the vaccine because 42 days
is the maximum incubation period of the mumps virus. They took all person-days between one
year and 42 days prior to AM onset as control times (excluding days when the subject was less
than 6 months old). They estimated a ratio of 5.5 (95% CI 2.6, 11.8) for one strain of the vaccine
and 0.6, (95% CI = 0.18,1.97) for another.
3 A Natural Estimand
Consider a randomized trial in which treatment is randomly assigned at time k to all subjects
who have yet to experience the outcome. Such a trial could estimate the immediate effect of
treatment at time k. This hazard ratio, assumed constant over k, would be a natural quantity
for the case-crossover estimator to target.
To formalize, we adopt the counterfactual framework of Robins (1986). Let Y a¯jij be the value
of the outcome at time j had, possibly contrary to fact, subject i followed treatment regime
a¯j ≡ (a1, . . . , aj) through time j. We refer to Y a¯jij as a counterfactual or potential outcome.
Since we will frequently consider treatment interventions at a single time point, we also introduce
the notation Y aj as shorthand for Y A¯j−1,aj , i.e. the counterfactual value of Yj under observed
treatment history through j−1 and treatment at time j set to aj . The randomized trial described
above conducted at time k would yield an estimate of ρmargk ≡ P (Y 1k = 1|Y¯k−1 = 0)/P (Y 0k =
1|Y¯k−1 = 0). (We include the marg superscript to emphasize that this hazard ratio is marginal
over values of V and U¯k. Why we stress this will become apparent later.) We asserted that
ρmarg ≡ ρmargk assumed constant over k (2)
might be a natural estimand for the case-crossover estimator. In the remainder of the paper, we
will see that, except under particularly strong assumptions, the estimator does not in general
quite converge to ρmarg, though the bias can sometimes be small.
4 Derivation of the Counterfactual Interpretation of the
Limit of the Case-Crossover Estimator
4.1 Assumptions
Our goal is to specify natural and near minimal assumptions that allow us to causally inter-
pret the limit of the case-crossover estimator. Most of our assumptions can be interpreted as
formalizations of informal assumptions (a)-(e).
Counterfactuals and the observed data are linked by the following standard assumption:
Consistency: Y A¯jj = Yj for all j. (3)
Consistency states that the counterfactual outcomes corresponding to the observed treatment
regimes are equal to the observed outcomes. Consistency is a technical assumption that has no
counterpart in the informal assumptions (a)-(e) but is implicit in almost all analyses.
The DAG in Figure 1 encodes informal assumption (b) that effects are transient. It specifically
implies that
Transient effects:Aj has no direct effect on Yj+1, . . . , YT not through Aj+1, . . . , AT
and Yj for all j.
(4)
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We might hope that (4) implies that counterfactual hazards are independent of past treatment
history, i.e. that λa¯jvj ≡ pv(Y a¯jj = 1|Y¯j−1 = 0) does not depend on a¯j−1. However, this is not
the case due to collider bias stemming from selection on survival and the presence of U¯T in
Figure 1 (Hernan et al., 2004). To avoid such collider bias, we consider counterfactual hazards
conditional on U . Let λajvj(a¯j−1, u¯j) denote pv(Y
aj
j = 1|Y¯j−1 = 0, A¯j−1 = a¯j−1, U¯j = u¯j), i.e.
the conditional counterfactual hazard at time j under treatment aj given past treatments a¯j−1,
potential common causes of outcomes u¯j , and baseline confounders v. We assume, as in Figure
1, that:
U-Transient Hazards: λajvj(a¯j−1, u¯j) does not depend on a¯j−1. (5)
That is, conditional on the history of U , the current counterfactual hazard does not depend
on past treatments. This assumption is consistent with the absence of any mention of such a
possible dependence in the case crossover literature.
Biological considerations determine the plausibility of (4) and (5). In the vaccine study,
person-times were deemed treated for 42 days (the maximum incubation period for the mumps
virus) after vaccination. Assumptions (4) and (5) would be violated if meningitis results from
cumulative activity of the mumps virus over many days. In the MI study, (4) and (5) would be
violated if exercise can have cumulative or delayed effects on MI.
Under (5), we can define the u-counterfactual hazard λajvj(u¯j) under treatment aj at time j as
λ
aj
vj(a¯j−1, u¯j) for any a¯j−1. The causal hazard ratio at time j given u¯j is then λ
1
vj(u¯j)/λ
0
vj(u¯j).
We assume that this causal hazard ratio is constant:
Constant Hazard Ratio: β ≡ βvj(u¯j) ≡ λ1vj(u¯j)/λ0vj(u¯j) does not depend on v, j, or u¯j .
(6)
(6) is a strengthening of the usual constant effects assumption (e), which does not mention time or
post-baseline common causes of the outcome. (6) also makes stronger homogeneity assumptions
than (2), which only assumes constant hazard ratios at each time as opposed to constant hazard
ratios conditional on time, v, and u¯j . Under the constant hazard assumption (6), β = ρmarg
from (2) and the trial described in Section 3 would target β.
(6) is a very strong assumption unlikely to ever hold exactly. Violations can be less extreme
among subpopulations, e.g. subjects who exercise regularly in the MI study. When we analyze
the Mantel-Haenszel estimator in Sections 4.3 and 5.2, we will see that if (6) fails then the
estimator will not converge to the trial estimand ρmarg. We examine sensitivity to violations of
(6) in Section 5.2.
The DAG in Figure 1 also encodes informal assumption (c) that there are no post-baseline
confounders not contained in V . We formalize the assumption in terms of counterfactuals:
Sequential Exchangeability: Aj ⊥
{
Y a¯kk ; k ≥ j
} |Y¯j−1 = 0, A¯j−1 = a¯j−1, V = v for all j
(7)
An example of a hypothetical violation of (7) in the MI study would be if caffeine intake at hour
j encouraged exercise and increased MI risk at j.
We make the assumption that the outcome is rare within levels of V and A.
Rare Outcome: Pv(Yj = 1|A¯j = a¯j , Y¯j−1 = 0) < ∀j, v, a¯j (8)
We do not use this assumption in our main result (Theorem 1), but we will see in section 5.1
that it is required to ensure that a certain bias is small. We will also see in Remark 3 that it
allows us to to state our no time trends in treatment assumption interpretably.
There is a straightforward intuitive motivation behind informal assumption (d) that there are
no time trends in treatment. Because control times always precede case times, a steady change in
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treatment probability over time would result in a preponderance of discordant pairs of one type
over the other in equation (1) even in the absence of any causal effect of treatment on outcome.
Our version of informal assumption (d) is the following:
Conditional pairwise exchangeability:
pv(Ak = 1, Ac = 0) ≈ pv(Ak = 0, Ac = 1)∀v, k, c such that c might be a control time if the
outcome were to occur at k.
(9)
We actually require a more mathematically complex assumption (21), which is stated in
the proof of Theorem 1. However, under rare outcome assumption (8), the more complicated
assumption (21) approximately reduces to the more interpretable (9), as we explain in Remark 3
following the proof of the theorem. Vines and Farrington (2001) originally derived the necessity
of pairwise exchangeability. This condition holds when the marginal probability of exposure at
each time k at which an outcome might occur is equal to the marginal probabilities of exposure
at all times that could be used as control times were the outcome to occur at k, which can
be interpreted as a more precise formulation of “no time trends in treatment”. Whether this
assumption holds depends in part on how control times are chosen. In the MI study, for example,
control times 12 hours prior to the outcome could be much less likely to satisfy (9) than control
times 24 hours prior (e.g. 2PM the previous day would be a better control time than 2AM the
morning of an MI that occurred at 2PM). The vaccine study would violate (9) if vaccination
probability is associated with age.
Remark 1. Assumption (9) is actually doing double duty. Unlike informal assumption (d) or
Vines and Farrington (2001), our assumption (9) is stated within levels of V . In addition to
preventing bias from time trends in treatment alone, it also prevents bias from so called time-
modified baseline confounders (Platt et al., 2009) whose effect on treatment can vary over time,
e.g. make (Ak = 0, Ac = 1) more or less likely than (Ak = 1, Ac = 0) while also impacting
the outcome. The case-crossover literature distinguishes between baseline and post-baseline con-
founders and says the former are allowed but the latter are not. The more relevant distinction
is actually whether a confounder has time-varying effects.
To understand the issue, first consider a post-baseline confounder. We gave the example
earlier of caffeine intake at time j impacting probability of exercise at time j and probability of
MI at time j. Let Cj denote caffeine at time j. Cj is temporally a post-baseline variable as its
value is realized at time j, but mathematically and in the causal ordering it could be equivalent
to a baseline variable if it is not influenced by past treatments. For example, coffee at time j
could be equivalent to taking a j-hour delayed release caffeine pill at baseline. Suppose Z(j) ∈ V
is a baseline variable such that Z(j) = 1 causes Aj = 1 and Yj = 1 to be more likely. Z(j)
would induce bias just as Cj would, even though Z(j) is a baseline confounder contained in V
that would not lead to a violation of (7). However, the existence of such a Z(j) would violate
(9), illustrating how (9) protects us from time-modified confounding bias.
4.2 The Mantel-Haenszel estimator
We now formally define the standard outcome-censored case-crossover design and the Mantel-
Haenszel estimator.
Outcome censored case-crossover design:
• Select a random sample of H person-times from the H∗ person times ij satisfying Yij = 1,
Yi(j−1) = 0, j > W where W is a maximum ‘look back’ time chosen by the investigator.
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These H∗ person times ij are those in which the outcome for person i occurred for the
first time at j, subject to j > W. We refer to these H∗ person-times as the set of ‘case’
person-times.
• Let ihjh denote the person-time of the hth element of the set of H sampled case person
times. From the same subject ih, we select mh times {jh − c1, . . . , jh − cmh} from the
W times prior to the time jh of subject i′hs first outcome event. We call these mh times
the ‘control’ person-times for subject ih. For simplicity, in our analysis we assume that
mh = m and {c1, . . . , cm} are constant across subjects. We discuss selection of ‘control’
times below.
• Let A1h denote the treatment Aihjh at the time jh of the first outcome in subject ih and
(A0h1, . . . , A
0
hm) denote that subject’s treatments at them control times (Acjh,1 , . . . , Acjh,m).
The MH case-crossover estimator ÎRRMH is defined to be
ÎRRMH =
∑
h
∑m
l=1 1{A1h = 1, A0hl = 0}∑
h
∑m
l=1 1{A1h = 0, A0hl = 1}
. (10)
Note that for subject ih the only data necessary to compute ÎRRMH is (A1h, A
0
h1, . . . , A
0
hm).
Many approaches to selecting a set of control times from the W person-times prior to the
outcome might be acceptable. In our MI example, the lookback window is the 24 hours before the
MI and there is only one control time exactly 24 hours before the outcome time for all sampled
subjects. So W = 24, m = 1, and c1 = 24. In the vaccine example, all days between 365 and 42
days prior to the outcome on which the subject is at least six months old are controls. Since mh
depends on subject age under this scheme, a slight modification of our analysis is necessary to
accommodate the vaccine example.
4.3 The limit of the Mantel-Haenszel estimator
We now derive the limit of ÎRRMH in the outcome-censored case-crossover design under an
asymptotic sequence in which N →∞, H∗/N → c1 > 0, and H/H∗ → c2 > 0.
Theorem 2. Suppose the consistency (3), transient effects (4), U-transient hazards (5), constant
hazard ratio (6), sequential exchangeability (7), and no time trends in treatment (21) (defined in
the proof below) assumptions all hold. Then, under the outcome-censored case-crossover design,
ÎRRMH
p→ β
∑m
l=1
∫
v
∑
k>W
∑
u¯k
αvkl(u¯k)p(v)dv∑m
l=1
∫
v
∑
k>W
∑
u¯k
1−βλ0v,k−cl (u¯k−cl )
1−λ0v,k−cl (u¯k−cl )
αvkl(u¯k)p(v)dv
where αvkl(u¯k) = λ0vk(u¯k)
∑
a¯k/k,k−cl
pv(Y¯k−1 = 0, Ak = 1, Ak−cl = 0, A¯k/k,k−cl = a¯k/k,k−cl , U¯k =
u¯k).
Proof. From the definition of ÎRRMH , it is clear that under the outcome-censored case-crossover design
ÎRRMH
p→
∑m
l=1 Pr(A
1 = 1, A0l = 0)∑m
l=1 Pr(A
1 = 0, A0l = 1)
, (11)
where Pr(A1 = a,A0l = a
′) is the probability that a randomly selected subject who experienced an
occurrence of the outcome at least W+1 time steps after baseline will have treatment level a at the time
of the outcome and that the lth selected ‘control’ time from the duration W lookback period preceding
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the event in the same subject will have treatment level a′. For notational simplicity, we present the proof
for the case where m = 1 and, if the outcome occurs at time k, there is one control time k − c. W = c
in this simple scenario. According to this sampling scheme, we can express (11) as
Pr(A1 = 1, A0 = 0)
Pr(A1 = 0, A0 = 1)
(12)
=
∫
v
∑
k>W
∑
a¯k/k,k−c,u¯k
pv(Yk = 1, Y¯k−1 = 0, Ak = 1, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k)p(v)dv∫
v
∑
k>W
∑
a¯k/k,k−c,u¯k
pv(Yk = 1, Y¯k−1 = 0, Ak = 0, Ak−c = 1, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k)p(v)dv
(13)
=
∫
v
∑
k>W
∑
a¯k/k,k−c,u¯k
βvk(u¯k)λ
0
vk(u¯k)pv(Y¯k−1 = 0, Ak = 1, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k)p(v)dv∫
v
∑
k>W
∑
a¯k/k,k−c,u¯k
λ0vk(u¯k)pv(Y¯k−1 = 0, Ak = 0, Ak−c = 1, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k)p(v)dv
(14)
= β
∫
v
∑
k>W
∑
u¯k
λ0vk(u¯k)
∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 1, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k)p(v)dv∫
v
∑
k>W
∑
u¯k
λ0vk(u¯k)
∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 0, Ak−c = 1, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k)p(v)dv
(15)
where a¯k/k,k−c denotes a¯k excluding ak and ak−c. We go from (12) to (13) by basic probability rules;
(13) to (14) by consistency (3), U-transient hazards (5), and Sequential Exchangeability (7); and (14) to
(15) by Constant Hazard Ratio (6). Any bias in the estimator must result from the difference between∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 1, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k) (16)
and ∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 0, Ak−c = 1, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k). (17)
We can expand (16) in terms of conditional probabilities as follows.
∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 1, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k) =
∑
a¯k/k,k−c
{pv(Ak = 1|Y¯k−1 = 0, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k)×
k−1∏
s=k−c+1
pv(as|Y¯s−1 = 0, Ak−c = 0, A¯s−1k/k,k−c = a¯s−1/k−c, U¯s = u¯s)×
pv(Ak−c = 0|Y¯k−c−1 = 0, A¯k−c−1 = a¯k−c−1, U¯k−c = u¯k−c)×
k−c−1∏
s=1
pv(as|Y¯s−1 = 0, A¯s−1 = a¯s−1)}×
{
∏
s>k−c
pv(us|Y¯s−1 = 0, A¯s−1/k−c = a¯s−1/k−c, Ak−c = 0, U¯s−1 = u¯s−1)×∏
s≤k−c
pv(us|Y¯s−1 = 0, A¯s−1 = a¯s−1, U¯s−1 = u¯s−1)}×∏
s 6=k−c,k
(1− λasv,s(u¯s))× (1− λ0v,k−c(u¯k−c))
(18)
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By (4) and (7), A can be removed from any conditioning event of a U and vice versa. Thus, we can
re-express (16) as:∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 1, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k) =
(1− λ0v,k−c(u¯k−c))Mk×
{
∑
a¯k/k,k−c
pv(Ak = 1|Y¯k−1 = 0, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c)×
k−1∏
s=k−c+1
pv(as|Y¯s−1 = 0, Ak−c = 0, A¯s−1k/k,k−c = a¯s−1/k−c)×
pv(Ak−c = 0|Y¯k−c−1 = 0, A¯k−c−1 = a¯k−c−1)×
∏
s 6=k−c,k
(1− λasv,s(u¯s))},
(19)
where we have grouped some terms not depending on a¯k/k,k−c into Mk. We can then write (17) as∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 0, Ak−c = 1, A¯k/k,k−c = a¯k/k,k−c, U¯k = u¯k) =
1− λ1v,k−c(u¯k−c)
1− λ0v,k−c(u¯k−c)
(1− λ0v,k−c(u¯k−c))Mk×
{
∑
a¯k/k,k−c
pv(Ak = 0|Y¯k−1 = 0, Ak−c = 1, A¯k/k,k−c = a¯k/k,k−c)×
k−1∏
s=k−c+1
pv(as|Y¯s−1 = 0, Ak−c = 1, A¯s−1k/k,k−c = a¯s−1/k−c)×
pv(Ak−c = 1|Y¯k−c−1 = 0, A¯k−c−1 = a¯k−c−1)×
∏
s6=k−c,k
(1− λasv,s(u¯s))}
(20)
Letting
Gv(Ak = a,Ak−c = a
′
, u¯k) ≡∑
a¯k/k,k−c
pv(Ak = a|Y¯k−1 = 0, Ak−c = a
′
, A¯k/k,k−c = a¯k/k,k−c)
k−1∏
s=k−c+1
pv(as|Y¯s−1 = 0, Ak−c = a
′
, A¯s−1k/k,k−c = a¯s−1/k−c)
pv(Ak−c = a
′ |Y¯k−c−1 = 0, A¯k−c−1 = a¯k−c−1)
k−c−1∏
s=1
pv(as|Y¯s−1 = 0, A¯s−1 = a¯s−1)
∏
s 6=k,k−c
(1− λasvs(u¯s)),
we make the assumption that
No Time Trends in Treatment: Gv(Ak = 1, Ak−c = 0, u¯k) = Gv(Ak = 0, Ak−c = 1, u¯k) for all v, k, c, u¯k.
(21)
No time trends in treatment (21) now implies that (19) and (20) (and therefore (16) and (17)) are equal
except for the factor
1−λ1v,k−c(u¯k−c)
1−λ0
v,k−c(u¯k−c)
. Returning to (15), we now have
Pr(A1 = 1, A0 = 0)
Pr(A1 = 0, A0 = 1)
= β
∫
v
∑
k
∑
u¯k
αvk(u¯k)p(v)dv∫
v
∑
k
∑
u¯k
1−βλ0
v,k−c(u¯k−c)
1−λ0
v,k−c(u¯k−c)
αvk(u¯k)p(v)dv
(22)
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where αvk(u¯k) denotes λ0vk(u¯k)
∑
a¯k/k,k−c
pv(Y¯k−1 = 0, Ak = 1, Ak−c = 0, A¯k/k,k−c = a¯k/k,k−c, U¯k =
u¯k).
There are a few takeaways from this result and its proof. First, the Mantel-Haenszel esti-
mator is not generally consistent for β, but would be consistent were it not for the bias terms
1−βλ0v,k−cl (u¯k−cl )
1−λ0v,k−cl (u¯k−cl )
, which we discuss in detail in the following section. Second, inspecting (14) re-
veals the necessity of the constant hazard ratio assumption (6). Without (6), even in the absence
of the bias terms in the denominator the estimator’s limit is a weighted average of effects with
difficult to interpret weights.
Remark 3. Consider the technical no time trends in treatment assumption (21). Under rare
outcome assumption (8), we can remove Y¯j−1 = 0 from all conditioning events in Gv(Ak =
a,Ak−c = a
′
, u¯k) without much consequence and
∏
s6=k−c,k(1 − λasv,s(u¯s)) ≈ 1. Then the LHS
of (21) becomes pv(Ak = 1, Ak−c = 0), and the RHS becomes pv(Ak = 0, Ak−c = 1), i.e the
assumption reduces to conditional pairwise exchangeability (9). Thus, (9) is an easy-to-interpret
assumption that is implied by the more technical (21) under (8).
(21) is a stronger assumption than is strictly needed. In Web Appendix B, we discuss alter-
native weaker assumptions. We chose (21) because: A) its approximate equivalent (9) is easier
to reason about than the alternative assumptions; and B) for (21) to fail when the alternative
assumptions hold requires some fortuitous averaging out.
Remark 4. Under stronger alternative assumptions, we can eliminate the bias term in Theorem
1. Equations (14), (19), and (20) from the proof of Theorem 1 together imply that under the
assumptions of Theorem 1 the limit of the case-crossover estimator can be written:∫
v
∑
k>W
∑
u¯k
λ1vk(u¯k)
λ0vk(u¯k)
1−λ0vk−c(u¯k−c)
1−λ1vk−c(u¯k−c)
αvk(u¯k)p(v)dv∫
v
∑
k>W
∑
u¯k
αvk(u¯k)p(v)dv
(23)
where αvk(u¯k) is as in Theorem 1. If we make a homogeneous hazards assumption
Homogeneous Hazards: λavk(u¯k) = λ
a
vk−c(u¯k−c)
for all times k, corresponding control periods k − c, a, v, u¯k
(24)
then (23) is equal to ∫
v
∑
k>W
∑
u¯k
ORvk(u¯k)αvk(u¯k)p(v)dv∫
v
∑
k>W
∑
u¯k
αvk(u¯k)p(v)dv
(25)
with ORvk(u¯k) =
λ1vk(u¯k)
λ0vk(u¯k)
1−λ0vk(u¯k)
1−λ1vk(u¯k)
the causal odds ratio at time k given U¯k = u¯k. If we then
further assume a constant causal odds ratio
Constant Causal Odds Ratio: βOR ≡ ORvk(u¯k) for all k, v, u¯k (26)
then (25) implies the case-crossover estimator is consistent for βOR under the assumptions of
Theorem 1 plus (24) and (26). And under the rare outcome assumption, βOR ≈ β. (24) seems a
particularly strong assumption, since it essentially supposes that no time-varying variable except
for the exposure can influence the hazard.
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5 Analysis of selected sources of bias
5.1 Bias due to Common Causes of the Outcome
Examining the multiplicative bias term
1− βλ0v,k−cl(u¯k−cl)
1− λ0v,k−cl(u¯k−cl)
(27)
from Theorem 1, the first thing to note is that when β = 1 the bias term (27) is equal to 1, i.e.
there is no bias. Hence, under the assumptions of Theorem 1, the case-crossover estimator leads
to valid hypothesis tests of the causal null. The next thing to note is that under rare outcome
assumption (8), if there are no common causes U of outcomes at different person times other
than V , then (27) is negligible and the case crossover estimator is approximately a consistent
estimator of β. And even if there are common causes U of the outcomes but the outcome is
rare at all values of U , then (27) is still negligible. However, when β 6= 1, common causes of the
outcome are present, and the outcome is not rare at some levels of those common causes (even if
(8) holds marginal over U), then substantial bias may be present. This bias will be particularly
large when U is a strong common cause of the outcome at case and control times k and k−cl (i.e.
when λ0v,k−cl(u¯k−cl) and λ
0
vk(u¯k) tend to be high for the same values of u¯k). In this case, the
bias term (27) is systematically large when the λ0vk(u¯k) term in αvk(u¯k) is large in (22), leading
to substantial bias. Further, the bias term (27) always pushes the estimate away from the null.
That is, the limiting value of the biased estimate is further from the null value of 1 than the true
β (and in the same direction). This bias that can appear when the outcome is rare marginally
but not rare within levels of common causes of the outcome has not been previously identified
to our knowledge.
We illustrate with a simulation. For N = 100, 000 subjects, we simulated treatments and
counterfactual outcomes until the first occurrence of the outcome according to the following data
generating process (DGP). See Web Appendix A for R code.
Ut ∼ Bernoulli(.005); λ0t (Ut−1, Ut) = min(1/2, .45Ut−1 + .45Ut)
Y 0t ∼ Bernoulli(λ0t (Ut−1, Ut)); λ1t (Ut−1, Ut) = 2λ0t (Ut−1, Ut)
Y 1t ∼ Bernoulli(λ1t (Ut−1, Ut)); At ∼ Bernoulli(.5)
Yt = AtY
1
t + (1−At)Y 0t
The DAG for this DGP is depicted in Figure 2. The true value of β is 2. There are no
common causes of treatments and outcomes, treatments are independent identically distributed
and hence exhibit no time trends, and the outcome is rare marginal over U . (While the outcome
is not rare when Ut = 1, it is rare that Ut = 1.) Yet the limit of the case-crossover estimator
using the time prior to outcome occurrence as the control is approximately 2.8. The estimator
fails because the outcome was common when U = 1 and U had strong common effects on the
outcome at case and control times.
We can directly understand how U impacts the case-crossover estimator (10) by reducing the
frequency of discordant pairs in which the control time is exposed, thus increasing the estimator
by decreasing the count in its denominator. The sequence (Ut−1 = 1, At−1 = 1, Yt−1 = 0, At =
0, Yt = 1) is particularly unlikely, since Yt−1 is likely to equal 1 when Ut−1 = 1 and At−1 = 1 as
a result of Ut−1 = 1 increasing the baseline risk of Yt−1. And because Ut−1 = 1 also increases
the probability of Yt = 1, there will be many cases contributing to the estimator in which this
dynamic was at play. A recently formed blood clot could roughly play the role of U in the MI
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Figure 2: Causal DAG for simulation DGP with unobserved post-baseline common causes of
outcomes at different times
example–a rare event that does not influence probability of exposure and greatly increases the
probability of the outcome at multiple time points after the clot forms.
5.2 Treatment Effect Heterogeneity
We now examine sensitivity to violations of the constant causal hazard ratio assumption. For
simplicity, we consider a scenario where there are just two types of subjects and counterfactual
hazard ratios are constant across time within types. For g ∈ {0, 1}, say subjects of type g arise
from the following data generating process:
A1, . . . , AT
iid∼ Bernoulli(pA,g); Y 01 , . . . , Y 0T iid∼ Bernoulli(λ0g)
Y 11 , . . . , Y
1
T
iid∼ Bernoulli(λ1g); Yj = AjY 1j + (1−Aj)Y 0j
with data censored at the first occurrence of the outcome. So within each type g, the constant
causal hazard ratio is λ1g/λ0g. Let pg denote the proportion of the population of type g =
1. According to equation (14), if the rare outcome assumption holds then the case-crossover
estimator with m=1 (i.e. using just one control) will approach
λ1g=1pA,g=1(1− pA,g=1)pg + λ1g=0pA,g=0(1− pA,g=0)(1− pg)
λ0g=1pA,g=1(1− pA,g=1)pg + λ0g=0pA,g=0(1− pA,g=0)(1− pg)
. (28)
(28) can be expressed as a weighted average of λ1g=0/λ0g=0 and λ1g=1/λ0g=1,
λ1g=0
λ0g=0
δ
δ + θ
+
λ1g=1
λ0g=1
θ
δ + θ
,
where δ = λ0g=0pAg=0(1− pA,g=0)(1− pg) and θ = λ0g=1pA,g=1(1− pA,g=1)pg. Hence, the limit of
the case-crossover estimator is bounded by the group-specific hazard ratios.
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The relative risk computed from the RCT described in Section 3 would approach
λ1g=1pg + λ
1
g=0(1− pg)
λ0g=1pg + λ
0
g=0(1− pg)
. (29)
Like the case-crossover limit, the RCT estimand can be expressed as a weighted average of
λ1g=0/λ
0
g=0 and λ1g=1/λ0g=1:
λ1g=0
λ0g=0
λ0g=0(1− pg)
λ0g=0(1− pg) + λ0g=1pg
+
λ1g=1
λ0g=1
λ0g=1pg
λ0g=0(1− pg) + λ0g=1pg
. (30)
Without loss of generality assume λ
1
g=0
λ0g=0
>
λ1g=1
λ0g=1
. The ratio of the weight placed on the higher
hazard ratio to the weight placed on the lower hazard ratio in the RCT estimand is
γRCT ≡
λ0g=0(1− pg)
λ0g=1pg
. (31)
The corresponding case-crossover weight ratio is
γCC ≡
λ0g=0(1− pg)pA,g=1(1− pA,g=1)
λ0g=1pgpA,g=0(1− pA,g=0)
= γRCT × pA,g=0(1− pA,g=0)
pA,g=1(1− pA,g=1) . (32)
(32) implies that bias of the case-crossover estimator due to treatment effect heterogeneity de-
pends on the difference in treatment probability between groups with different effect sizes. If
treatment probability does not vary across groups with different treatment effects, effect hetero-
geneity will not induce bias in the case-crossover estimator. When treatment probabilities do
vary, whichever group has higher treatment variance pA,g(1 − pA,g), i.e. whichever group has
probability of treatment closer to .5, will be weighted too highly by the case-crossover estima-
tor compared to the RCT estimand. Some intuition behind this behavior is that the closer the
treatment probability within a group is to .5, the more subjects from that group will contribute
discordant case-control pairs to the estimator, weighting the estimator disproportionately toward
the effect within that group.
For illustrative purposes, consider a numerical example where we set:
λ0g=0 = .001; λ
1
g=0 = .002; λ
0
g=1 = .0005; λ
1
g=1 = .005; pA,g=0 = .8; pA,g=1 = .5; pg = .5.
Then λ1g=1/λ0g=1 = 10, λ1g=0/λ0g=0 = 2, and the estimand (29) is equal to 4.67. ÎRRMH converges
to 5.5, while the naive cohort hazard ratio estimator P (Y=1|A=1)P (Y=1|A=0) that does not adjust for the
confounder g approaches 4.9. In this example, bias from effect heterogeneity overrides any
benefits from adjustment for unobserved confounding. (While we set baseline outcome risks to
be different across levels of g in this example, note that (32) implies this plays no role in inducing
bias due to effect heterogeneity.)
Treatment effect heterogeneity was present in both of our running examples. In the vaccine
example, only one strain of the vaccine seemed to significantly increase the risk of meningitis. In
the MI study, the effect of exercise appeared much greater in subjects who rarely exercised than
in those who exercised regularly. In the MI study, probability of treatment (i.e. exercise) by
definition varied considerably between regular and rare exercise groups. Hence, by our analysis
above, we would expect an estimate of the marginal effect to be biased. In each study, the authors
reported separate effect estimates for each of the strata over which the effect was thought to vary.
This is appropriate, as marginal effect estimates for the full population can be misleading.
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6 Discussion
We have put the case-crossover estimator on more solid theoretical footing by providing a proof of
its approximate convergence to a formal counterfactual causal estimand, β, under certain causal
assumptions. This consistency result alone may not be of much direct utility to practitioners,
but it was overdue for such a widely used method. And the derivation yielded some practical
insights as byproducts.
While most of the formal assumptions required for the estimator’s consistency map to the
commonly cited informal assumptions (a)-(e), we also discovered a new source of potential bias.
If the treatment effect is non-null and the outcome is not rare at some level of a common cause
of the outcome at different times, then the case crossover estimator can be biased away from the
null. We analytically characterized the size and direction of this bias and illustrated its potential
significance with a simulation. In our simulation, the effect of the common cause on the outcome
was quite strong, but the fact that U can be high dimensional (containing arbitrarily many
factors contributing to the outcome) increases the plausibility of a similar situation arising in a
real analysis.
Second, expression (14) characterizing the limit of the case-crossover estimator allowed us to
quantify sensitivity to violations of the constant treatment effect assumption. We analyzed a
simple scenario with two groups of subjects having potentially different baseline risks, exposure
rates, and treatment effects. All assumptions required for consistency apart from effect homo-
geneity were satisfied. We found that the limit of the case-crossover estimator is a weighted
average of the group-specific hazard ratios. The bias of the case-crossover estimator relative
to the estimand (2) that would be targeted by a RCT depends on the exposure rates in the
groups. If the groups have the same exposure rate, effect heterogeneity would not induce any
bias. Otherwise, whichever group had exposure rate closer to 0.5 would be overweighted. Bias
did not depend on the baseline hazards in the groups. We provided a numerical example in which
significant unobserved baseline confounding (which could be adjusted for by the case-crossover
estimator) and effect heterogeneity were both present. In this example, the effect heterogeneity
bias in the case-crossover estimator was greater than the confounding bias in a standard cohort
hazard ratio estimator. The example illustrated that effect heterogeneity can sometimes override
benefits from control of unobserved baseline confounding in the case-crossover estimator.
The essential implication of our findings for practitioners is that additional caution is war-
ranted when interpreting point estimates of causal effects from case-crossover designs. If interest
lies only in testing the null hypothesis of no effect, fewer assumptions are necessary. Under the
null: the transient treatment assumptions automatically hold; common causes of the outcome do
not induce bias; the rare outcome assumption is not necessary; and there is no treatment effect
heterogeneity. Hence, the case-crossover design remains a clever method for causal null hypoth-
esis testing in the presence of unmeasured baseline confounders under the exchangeability (7)
and no time trends in treatment (9) assumptions. However, when assessing the feasibility of (9),
recall its implication (discussed in Remark 1, but not discussed elsewhere in the case-crossover
literature to our knowledge) that baseline confounders cannot be time-modified.
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8 Appendix A: R code for simulation in Section 5.1
N=100000
sim_pat = function(p_U=.005,beta_U=.45,beta_last_U=.45,p_A=.5,int=0,hr=2){
last_U = 0
Y = 0
n=0
last_A=0
while(Y==0){
n=n+1
U = rbinom(1,1,p_U)
A = rbinom(1,1,p_A)
Y_0 = rbinom(1,1,min(1/hr,beta_U*U + beta_last_U*last_U + int))
Y_1 = rbinom(1,1,hr*min(1/hr,beta_U*U + beta_last_U*last_U + int))
Y = A*Y_1 + (1-A)*Y_0
last_U = U
last_A = Y*last_A + (1-Y)*A
}
if(n>=2){
return(c(last_A,A))
}else{
return(c(NA,A))
}
}
ests = rep(NA,100)
for(i in 1:100){
data = replicate(N,sim_pat())
D = t(data.frame(data))
D = D[!is.na(D[,1]),]
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mh = sum(D[,2]==1&D[,1]==0)/sum(D[,2]==0&D[,1]==1)
ests[i] = mh
}
9 Appendix B: Weaker Assumptions
Under the assumptions of Section 4.1 and the DAG in Figure 1, we have shown that we can write
the limit of the case-crossover estimator as
β
∫
v
∑
k>W
∑
u¯k
F 0v (u¯k)Gv(Ak = 1, Ak−c = 0, u¯k)p(v)dv∫
v
∑
k>W
∑
u¯k
F 1v (u¯k)Gv(Ak = 0, Ak−c = 1, u¯k)p(v)dv
(S1)
where
F av (u¯k) = λ
0
vk(u¯k)(1− λ0vk−c(u¯k−c))
∏
s6=k,k−c
pv(us|Y¯s−1 = 0, U¯s−1 = u¯Y s−1)
and
Gv(Ak = a,Ak−c = a
′
, u¯k) =∑
a¯k/k,k−c
pv(Ak = a|Y¯k−1 = 0, Ak−c = a′ , A¯k/k,k−c = a¯k/k,k−c)
k−1∏
s=k−c+1
pv(as|Y¯s−1 = 0, Ak−c = a′ , A¯s−1k/k,k−c = a¯s−1/k−c)
pv(Ak−c = a
′ |Y¯k−c−1 = 0, A¯k−c−1 = a¯k−c−1)
k−c−1∏
s=1
pv(as|Y¯s−1 = 0, A¯s−1 = a¯s−1)
∏
s6=k,k−c
(1− λasvs(u¯s))
Thus to avoid bias we need
∫
v
∑
k>W
∑
u¯k
F 0v (u¯k)Gv(Ak = 1, Ak−c = 0, u¯k)p(v)dv∫
v
∑
k>W
∑
u¯k
F 1v (u¯k)Gv(Ak = 0, Ak−c = 1, u¯k)p(v)dv
≈ 1 (S2)
One source of bias manifests through the disparity between 1 − λ0v,k−c(u¯Y k−c) in F 0v (u¯k) and
1− λ1v,k−c(u¯Y k−c) in F 1v (u¯k), which leads to the failure of (S2). In the absence of such bias (e.g.
if β = 1 or if the outcome is very rare both marginally and within levels of v and u¯k), we have
F 0v (u¯k) ≈ F 1v (u¯k) ≡ Fv(u¯k) and need∫
v
∑
k>W
∑
u¯k
Fv(u¯k)Gv(Ak = 1, Ak−c = 0, u¯k)p(v)dv∫
v
∑
k>W
∑
u¯k
Fv(u¯k)Gv(Ak = 0, Ak−c = 1, u¯k)p(v)dv
≈ 1
or, put slightly differently,∫
v
∑
k>W
∑
u¯k
Fv(u¯k){Gv(Ak = 1, Ak−c = 0, u¯k)−Gv(Ak = 0, Ak−c = 1, u¯k)}p(v)dv ≈ 0 (S3)
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Our No Time Trends in Treatment assumption sets Gv(Ak = 1, Ak−c = 0, u¯k) = Gv(Ak =
0, Ak−c = 1, u¯k) for all v and u¯k, which makes the integrand of (S3) (and of course therefore the
full integral in (S3)) exactly 0. This is an unnecessarily strong assumption.
For example, we could instead assume:∫
v
∑
k>W
∑
u¯k
(Gv(Ak = 1, Ak−c = 0, u¯k)−Gv(Ak = 0, Ak−c = 1, u¯k))p(v)dv = 0 (S4)
and ∫
v
∑
k>W
∑
u¯k
Fv(u¯k){Gv(Ak = 1, Ak−c = 0, u¯k)−Gv(Ak = 0, Ak−c = 1, u¯k)}p(v)dv
=
∫
v
∑
k>W
∑
u¯k
Fv(u¯k)p(v)dv×∫
v
∑
k>W
∑
u¯k
{Gv(Ak = 1, Ak−c = 0, u¯k)−Gv(Ak = 0, Ak−c = 1, u¯k)}p(v)dv
(S5)
Together, (S4) and (S5) clearly imply (S3), as desired. And since both (S4) and (S5) are
implied by (21), they are weaker assumptions. (S4) imposes the restriction that there are no
marginal time trends in treatment, but, unlike (21), allows trends within levels of V as long as
they cancel out. Even under (S4), (S3) can still fail if Gv(Ak = 1, Ak−c = 0, u¯k) − Gv(Ak =
0, Ak−c = 1, u¯k) is correlated with Fv(u¯k). (S5) prohibits this correlation, which can arise in the
presence of a time modified confounder. For example, suppose that (as in Remark 1) Z¯K ⊂ V
is a set of baseline iid variables Z1, . . . , ZK such that Zt causes At = 1 and Yt = 1 to be more
likely. Whenever Zk = 1 and Zk−c = 0, Gv(Ak = 1, Ak−c = 0, u¯k) − Gv(Ak = 0, Ak−c = 1, u¯k)
and λ0vk(u¯k) (and therefore Fv(u¯k)) will be large, inducing a correlation banned by (S5). Thus,
like (21), (S5) serves to ban time modified confounding.
In the main body of the paper, we use the stronger assumption (21) because we believe it
is simpler for practitioners to assess its plausibility (at least under a rare outcome assumption
when it reduces to (9)) and because it would require some fortuitous canceling out for (S4) and
(S5) to hold if (21) does not. Also, assuming (21) allows us to more conveniently analyze the
bias caused independently by U .
10 Appendix C: Assessment of the Exercise and MI Study
It might be illustrative to assess our simplified version of Mittelman et al.’s (1993) seminal
study on the impact of exercise on MI through the lens of the framework we developed. We
define treatment to be vigorous exercise in the previous hour and our lookback period to be 24
hours. We assume that data collection occurs over the course of a single Sunday, so we take
the baseline for the underlying cohort population of interest to be midnight of the preceeding
Saturday morning. We will consider each of the causal and distributional assumptions that we
have discussed in the context of this simplified study.
First, we consider whether the DAG in Figure 1 is likely to describe the data generating
process within levels of V :
No Post-Baseline Confounders (assumption (7)). In the paper, we discussed the example of
drinking coffee as a possible violation of this assumption. Caffeine might increase energy and
encourage exercise and also independently increase the risk of MI. We might reasonably hope
that confounders of this sort (short term encouragements to exercise that are also associated
with MI) are weak.
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No Direct Effect of Treatment on Later Outcomes (assumptions (4) and (5)). It seems likely
that exercise might have a cumulative effect on the outcome. Exercise in a given hour could
be more likely to cause an MI given exercise in the previous hour as well. Perhaps extended
vigorous exercise is rare enough that the cumulative effect of exercise does not seriously impact
results or their interpretation.
No Time Trends in Treatment Within Levels of V (assumption (9)). Marginal probability of
recent exercise varies greatly by time of day. If the control time is chosen appropriately (e.g. 1
hour or exactly 24 hours before the MI), then approximate pairwise exchangeability may hold.
However, it might be that within levels of certain baseline confounders exercise is more probable
on one of Saturday or Sunday at the same time of day. For example, perhaps the lifestyle of
a stereotypical NFL fan (beer, cholesterol) is a confounder that also makes exercise during the
afternoon on Sunday (when NFL games are played) less likely than Saturday. (This is a strained
and purely illustrative example.)
Under the above assumptions (in addition to Consistency), the case-crossover could reason-
ably be applied to test the causal null hypothesis. To interpret the case-crossover point estimate,
additional considerations are required.
Rare Outcome (V, A, and U). The outcome must be rare within all levels of the baseline
confounders, exposure, and common causes of the outcome. MIs are certainly rare marginally
at the level of a day, and probably also rare across levels of baseline confounders and exposures.
However, we mentioned that perhaps causes of the outcome such as presence of a clot could make
the outcome common, particularly under exposure. This would induce bias of the sort seen in
the simulation in Section 5.1.
Constant Causal Hazard Ratio. It is highly unlikely that the multiplicative effect of exercise
in each of the 24 hours on our Sunday is constant across the entire population. While true under
the null, this is a very strong assumption if the null does not hold. We can make it weaker
by further restricting our study population to subjects sharing baseline characteristics such as
age, gender, indications of general fitness, and cholesterol levels. Still, the assumption is strong,
and we saw in Section 6.2 that it is difficult to interpret the estimate if the effect is highly
heterogeneous.
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